Sandra Collette
European Organisation for Research and Treatment of Cancer(BE)
Publications by Year
Research Areas
Bladder and Urothelial Cancer Treatments, Urinary and Genital Oncology Studies, Cancer Immunotherapy and Biomarkers, Breast Cancer Treatment Studies, Glioma Diagnosis and Treatment
Most-Cited Works
- → Adjuvant Whole-Brain Radiotherapy Versus Observation After Radiosurgery or Surgical Resection of One to Three Cerebral Metastases: Results of the EORTC 22952-26001 Study(2010)1,982 cited
- → Imaging biomarker roadmap for cancer studies(2016)1,057 cited
- → A Prospective, Randomised EORTC Intergroup Phase 3 Study Comparing the Oncologic Outcome of Elective Nephron-Sparing Surgery and Radical Nephrectomy for Low-Stage Renal Cell Carcinoma(2010)1,041 cited
- → Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer(2015)1,010 cited
- → Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma(2021)987 cited
- → Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986(2011)767 cited
- → Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial(2014)671 cited
- → EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non–Muscle-invasive Stage Ta–T1 Urothelial Bladder Cancer Patients Treated with 1–3 Years of Maintenance Bacillus Calmette-Guérin(2015)623 cited
- → Randomized Phase III Study Comparing Paclitaxel/Cisplatin/ Gemcitabine and Gemcitabine/Cisplatin in Patients With Locally Advanced or Metastatic Urothelial Cancer Without Prior Systemic Therapy: EORTC Intergroup Study 30987(2012)531 cited
- → Final Results of an EORTC-GU Cancers Group Randomized Study of Maintenance Bacillus Calmette-Guérin in Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Urinary Bladder: One-third Dose Versus Full Dose and 1 Year Versus 3 Years of Maintenance(2012)503 cited